Daniel S. Mytelka

3.8k total citations · 1 hit paper
18 papers, 2.6k citations indexed

About

Daniel S. Mytelka is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Daniel S. Mytelka has authored 18 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Daniel S. Mytelka's work include Colorectal Cancer Treatments and Studies (6 papers), Sarcoma Diagnosis and Treatment (4 papers) and Neutropenia and Cancer Infections (4 papers). Daniel S. Mytelka is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Sarcoma Diagnosis and Treatment (4 papers) and Neutropenia and Cancer Infections (4 papers). Daniel S. Mytelka collaborates with scholars based in United States, Spain and United Kingdom. Daniel S. Mytelka's co-authors include Stacy Lindborg, Aaron L. Schacht, Christopher T. Dunwiddie, Bernard Munos, Steven M. Paul, Michael J. Chamberlin, Li Li, Lisa M. Hess, Astra M. Liepa and Sean D. Candrilli and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Nature Reviews Drug Discovery.

In The Last Decade

Daniel S. Mytelka

18 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

How to improve R&D productivity: the pharmaceutical industry's grand challenge

2010 2.3k citations Steven M. Paul, Daniel S. Mytelka et al. Nature Reviews Drug Discovery profile →

Peers

Daniel S. Mytelka

CTM

ONCOL

Stacy Lindborg United States

Aaron L. Schacht United States

Bernard Munos United States

Christopher T. Dunwiddie United States

John Arrowsmith United Kingdom

Michael Hay Australia

Jesse Rosenthal United States

David Cavalla United States

Tim Guilliams United Kingdom

Christine J. McNamee United Kingdom

Stacy Lindborg United States

Daniel S. Mytelka

1.0k ×1.0

830 ×1.0

CTM

544 ×1.3

340 ×1.0

177 ×0.7

ONCOL

Citations per year, relative to Daniel S. Mytelka Daniel S. Mytelka (= 1×) peers Stacy Lindborg

Countries citing papers authored by Daniel S. Mytelka

Since Specialization

Citations

This map shows the geographic impact of Daniel S. Mytelka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel S. Mytelka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel S. Mytelka more than expected).

Fields of papers citing papers by Daniel S. Mytelka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel S. Mytelka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel S. Mytelka. The network helps show where Daniel S. Mytelka may publish in the future.

Co-authorship network of co-authors of Daniel S. Mytelka

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel S. Mytelka. A scholar is included among the top collaborators of Daniel S. Mytelka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel S. Mytelka. Daniel S. Mytelka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Fisch, Michael, Michael Grabner, Daniel S. Mytelka, et al.. (2020). <p>Occurrence and Characteristics of Hospitalizations During First-Line Chemotherapy Among Individuals with Metastatic Colorectal Cancer</p>. Cancer Management and Research. Volume 12. 1535–1541. 1 indexed citations

Hess, Lisa M., Zhanglin Lin Cui, Daniel S. Mytelka, et al.. (2019). Treatment patterns and survival outcomes for patients receiving second-line treatment for metastatic colorectal cancer in the USA. International Journal of Colorectal Disease. 34(4). 581–588. 9 indexed citations

Nagar, Saurabh, Daniel S. Mytelka, Sean D. Candrilli, et al.. (2018). Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France. Sarcoma. 2018. 1–12. 31 indexed citations

Grothey, Axel, Takayuki Yoshino, G. Bodoky, et al.. (2018). Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set. ESMO Open. 3(3). e000347–e000347. 13 indexed citations

Mytelka, Daniel S., Saurabh Nagar, Yulia Dyachkova, et al.. (2018). Health Care Resource Utilization and Costs among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France. Sarcoma. 2018. 1–13. 3 indexed citations

Grothey, Axel, Josep Tabernero, Daniel S. Mytelka, et al.. (2017). Baseline absolute neutrophil counts (ANC) and survival in second-line metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology. 35(4_suppl). 713–713. 1 indexed citations

Mytelka, Daniel S., et al.. (2017). Post‐diagnosis weight loss as a prognostic factor in non‐small cell lung cancer. Journal of Cachexia Sarcopenia and Muscle. 9(1). 86–92. 35 indexed citations

Mytelka, Daniel S., María Gabriela Lorenzo, Dana Stafkey-Mailey, et al.. (2016). Advanced Soft Tissue Sarcoma: Systemic Treatment Patterns and Survival in Germany. Value in Health. 19(7). A760–A760. 2 indexed citations

Mytelka, Daniel S., María Gabriela Lorenzo, Dana Stafkey-Mailey, et al.. (2016). Real-World Treatment Patterns and Outcomes for Patients with Advanced Soft Tissue Sarcoma Receiving Systemic Therapy in The United Kingdom. Value in Health. 19(7). A751–A751. 3 indexed citations

10.

Ciuleanu, Tudor–Eliade, G. Bodoky, Rocio García‐Carbonero, et al.. (2016). Is neutropenia a prognostic or a predictive factor for second line metastatic colorectal cancer (mCRC) patients (Pts)? Exploratory analysis from RAISE, a randomized, double-blind, phase III study of ramucirumab (RAM) + FOLFIRI vs placebo (PBO) + FOLFIRI. Annals of Oncology. 27. vi198–vi198. 1 indexed citations

11.

Hess, Lisa M., et al.. (2015). Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data. Gastric Cancer. 19(2). 607–615. 51 indexed citations

12.

Chawla, Anita, Daniel S. Mytelka, Dave Nellesen, et al.. (2014). Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies. Pharmacoepidemiology and Drug Safety. 23(3). 268–277. 2 indexed citations

13.

Mytelka, Daniel S., Li Li, Dana Stafkey-Mailey, et al.. (2014). Treatment patterns and outcomes among patients with high-intermediate/high-risk diffuse large B-cell lymphoma in the USA. Hematology. 20(8). 442–448. 6 indexed citations

14.

Byfield, Stacey DaCosta, Emily Nash Smyth, Daniel S. Mytelka, Lee Bowman, & April Teitelbaum. (2013). Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population. Journal of Medical Economics. 16(12). 1379–1386. 19 indexed citations

15.

Ivanova, Jasmina, Daniel S. Mytelka, Mei Sheng Duh, et al.. (2013). Evaluating the Utility of Existing Patient-Reported Outcome Scales in Novel Patient Populations with Pancreatic Cancer, Lung Cancer, and Myeloproliferative Neoplasms Using Medicare Current Beneficiary Survey Data. Patient. 6(3). 189–200. 6 indexed citations

16.

Paul, Steven M., Daniel S. Mytelka, Christopher T. Dunwiddie, et al.. (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery. 9(3). 203–214. 2338 indexed citations breakdown →

17.

Mytelka, Daniel S. & Michael J. Chamberlin. (1996). Analysis and Suppression of DNA Polymerase Pauses Associated with a Trinucleotide Consensus. Nucleic Acids Research. 24(14). 2774–2781. 51 indexed citations

18.

Mytelka, Daniel S. & Michael J. Chamberlin. (1996). Escherichia coli fliAZY operon. Journal of Bacteriology. 178(1). 24–34. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact